Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exubera Efficacy In Type 1 Diabetes "Intensive" Control Questioned By FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer/Sanofi trial shows only 23% of Type 1 diabetes patients receiving inhaled insulin achieved standard of care for glycemic control, FDA tells advisory committee in briefing materials for Sept. 8 meeting.

You may also be interested in...



Pfizer/Sanofi Exubera Effective For Both Type 1 And Type 2 Diabetes, Committee Says

Advisory committee rejects FDA contention that inhaled insulin may not have shown intensive glycemic control in Type 1 diabetes.

Pfizer/Sanofi Exubera Effective For Both Type 1 And Type 2 Diabetes, Committee Says

Advisory committee rejects FDA contention that inhaled insulin may not have shown intensive glycemic control in Type 1 diabetes.

Pfizer's Exubera Inhaled Insulin To Be Reviewed By Endocrine Committee Sept. 8

Inhalation powder will be evaluated for diabetes mellitus in adults by FDA's Endocrinologic & Metabolic Drugs Advisory Committee. Developed in conjunction with Sanofi-Aventis, Exubera would be first inhaled insulin product.

Related Content

Topics

UsernamePublicRestriction

Register

PS062992

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel